{"ticker": {"uuid": "b8092b1e-4bd4-462a-bdf2-6cd4b56d7775", "symbol": "TCRT", "name": "Alaunos Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to earnings forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "The article references the price to earnings forward of Alaunos Therapeutics, Inc. under the NASDAQ:TCRT ticker. It appears to be a financial data page from TradingView, indicating that the market for TCRT was closed with no trades. The content primarily consists of navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T17:41:06", "published_display": "21 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "This article provides financial information for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), specifically its Price to Book Forward value. The content is presented within the TradingView platform, noting that market data is provided by ICE Data Services and reference data by FactSe", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T19:11:15", "published_display": "20 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "This article provides an enterprise value to revenue forward metric for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It focuses on financial data for the company, accessible through TradingView, and does not contain detailed analysis or news content. The piece appears to be a stub ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T00:39:26", "published_display": "19 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Alaunos Therapeutics Inc. on July 2nd. It is a brief financial news update from Investing.com, providing no further details within the article text itself.", "url": "https://uk.investing.com/news/stock-market-news/form-4-alaunos-therapeutics-inc-for-2-july-93CH-4755887", "source_name": "Investing.com UK", "published_at": "2026-07-06T22:38:00", "published_display": "06 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock grant to Alaunos (TCRT) CEO issued in lieu of salary", "summary": "Alaunos Therapeutics (TCRT) CEO Holger Weis received a stock grant of 3,880 common shares on June 30, 2026, as compensation in lieu of net salary. The shares were valued at $2.26 each, and following this transaction, Weis directly holds 16,552 common shares. This insider transact", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-ac15cf3b2c20.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:11:56", "published_display": "02 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical Development - Earnings Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZzNyR2UxX1pWLTR3cThXYVFnbHk5RjluTGttdEcxLWFGUDRYMVl2RkJpUV9rQmg4eHBGaHlBNEU4UVIyU0VXbWd3dXl4OEllRlljVHA0SkZESWMya2k5RHZYcmdFYk5tb0YxV1d3REtBR2hJM2g2RjdJZThGODJ6WVNkQmpPV0V1SlRuRzlyWHV4U043czgxbzkyakFjaTNaeGt0SkRyMTRLd1FzR0VGRTRMSlZycGREVU5oSjdQbw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:37:16+00:00", "published_display": "30 Jun 2026 07:37", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study", "summary": "Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in treated mice after adjusting for body fat percentage in a diet-induced obesity study. This finding supports previous data indicating ALN1003's potential for live", "url": "https://www.sahmcapital.com/news/content/alaunos-reports-new-preclinical-aln1003-data-showing-lower-liver-weight-after-adjustment-for-body-fat-percentage-in-48-day-dio-mouse-study-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-30T06:40:36", "published_display": "30 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings", "summary": "Alaunos Therapeutics announced new preclinical data for its investigational drug ALN1003, showing it significantly reduced liver weight in a diet-induced obesity mouse study, even after adjusting for body fat percentage. This finding is consistent with earlier data indicating low", "url": "https://www.stocktitan.net/sec-filings/TCRT/8-k-alaunos-therapeutics-inc-reports-material-event-70496303fa57.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:41:43", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) Stock News", "summary": "This page provides news and updates for Alaunos Therapeutics (TCRT) stock, focusing on its transition from TCR-T cell therapy to small-molecule therapeutics for obesity. Recent updates highlight preclinical results for ALN1003, an oral candidate for obesity, showcasing positive m", "url": "https://www.stocktitan.net/news/TCRT/", "source_name": "Stock Titan", "published_at": "2026-06-29T05:40:33", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT)", "summary": "This article provides an overview of Alaunos Therapeutics, Inc. (NASDAQ: TCRT) financials and stock performance. It includes details on historical and estimated financial data, stock price movements, volatility, net income, and upcoming earnings dates. The company currently has 1", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:29", "published_display": "26 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.32, ranking 126th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T16:10:29", "published_display": "24 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis", "summary": "Alaunos Therapeutics Inc (TCRT) currently has a valuation score of 6.29, placing it low within the Biotechnology & Medical Research industry. The company's P/E ratio is -1.04, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:35", "published_display": "19 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Alaunos Therapeutics Inc (TCRT), detailing its price momentum score of 5.75 and positioning between resistance at $2.85 and support at $1.68. It includes a summary of technical indicators and moving averages, which overwhelmingly sugg", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T02:09:09", "published_display": "19 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Alaunos Therapeutics Inc (TCRT), noting that no earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates that re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:50", "published_display": "18 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Alaunos Therapeutics Inc (TCRT), identifying its major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity, including ch", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:52", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Alaunos Therapeutics Inc (TCRT) stock split history and dividend payouts. The company has not distributed any dividends over the past five years. However, it has had several merger-related stock splits, including a 10-for-1 merger in July 2024", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:09:52", "published_display": "18 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown for Alaunos Therapeutics Inc (TCRT), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price, market cap, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:06", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary", "summary": "Alaunos Therapeutics CEO Holger Weis received a stock grant of 7,761 common shares valued at $2.26 per share on June 12, 2026. This grant was issued in lieu of his net salary, not through an open-market purchase. Following this transaction, Weis directly holds 12,672 shares of Al", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-21c7f242aaf1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:56", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Alaunos Therapeutics Inc (TCRT)'s institutional confidence score, financial data, and shareholder activity. It lists key institutional shareholders and their recent changes in shareholdings, showing that some increased their st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:39", "published_display": "17 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Alaunos Therapeutics Inc (TCRT), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of -1.06, indicating it tends to underperform in rising markets but declines less in falling ones. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-15T12:39:39", "published_display": "15 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "The article concerns the number of shareholders for Alaunos Therapeutics, Inc. (NASDAQ:TCRT). It provides a snapshot of the company's financial overview on TradingView, indicating no trades and a closed market status. The content primarily lists navigation elements and disclaimer", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-14T02:09:08", "published_display": "14 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk", "summary": "Alaunos Therapeutics (TCRT) stock fell 6.9% due to concerns over its limited cash reserves and an impending Nasdaq delisting risk, as its market cap is below compliance requirements. The company is attempting to shift investor focus to ALN1003, an early-stage obesity drug, despit", "url": "https://www.bez-kabli.pl/alaunos-therapeutics-tcrt-falls-on-cash-concerns-nasdaq-delisting-risk/", "source_name": "Bez Kabli", "published_at": "2026-06-04T13:09:07", "published_display": "04 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT - Alaunos Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and a news feed for Alaunos Therapeutics Inc (TCRT). It includes details on the company's oncology-focused cell therapy developments, recent preclinical study results for ALN1003, and past analyst rati", "url": "https://finviz.com/stock?t=TCRT", "source_name": "Finviz", "published_at": "2026-05-30T18:11:34", "published_display": "30 May 2026 18:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support Level - Short Setup Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNV29ibEJHVTlXdjc0a282NEljVExZRWNOZ1Q4eC1TMXBXcnlBY21PQ2xTRmI2dF9xZ2NRSjJtSU5WZ3lDNXZ3cjJDaXFMMG41dW1aZFRHX18zMmE5Wi1RVTBaSGZ0bzRfSDlSX1VxQjNtVno3X1lDbWFuaEVNSVJMWTNKTXc3bGx1Rl9uM2lFRE42dDQ0SmdVejcxMURjRTR0RlEzM2RqaDRTSXRqeTFwUE8zM1pjbkx6NVdtUnh3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary", "summary": "Alaunos Therapeutics (TCRT) CEO Holger Weis received 3,700 shares of common stock at $2.37 per share on May 22, 2026, as compensation in lieu of his net salary. Following this transaction, Weis directly holds 4,911 shares of Alaunos common stock. This insider activity was reporte", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-202df3217916.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:39:23", "published_display": "27 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers", "summary": "Alaunos Biomedical announced positive preclinical results for its new obesity drug, which demonstrated significant reductions in body weight, improved liver health, and enhanced insulin sensitivity in animal models. These findings suggest the drug could be a promising candidate f", "url": "https://www.msn.com/en-us/health/other/alaunos-reports-positive-preclinical-obesity-drug-results-across-weight-liver-insulin-markers/ar-AA247lNo?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-27T17:39:23", "published_display": "27 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports preclinical data for obesity drug candidate ALN1003 By Investing.com", "summary": "Alaunos Therapeutics has released integrated preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight and liver weight reductions in diet-induced obesity mouse studies. Despite these promising results and potential benefits for metabolic issu", "url": "https://za.investing.com/news/stock-market-news/alaunos-reports-preclinical-data-for-obesity-drug-candidate-aln1003-93CH-4300135", "source_name": "Investing.com South Africa", "published_at": "2026-05-26T17:10:24", "published_display": "26 May 2026 17:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alaunos-reports-broad-metabolic-improvements-150100200.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T15:01:00+00:00", "published_display": "26 May 2026 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers", "summary": "Alaunos Therapeutics announced positive preclinical results for ALN1003, an oral treatment for obesity and metabolic disorders, showing significant reductions in body weight and fat mass, improved insulin sensitivity, and enhanced liver health in diet-induced obese mice. While th", "url": "https://www.quiverquant.com/news/Alaunos+Therapeutics+Reports+Positive+Preclinical+Results+for+ALN1003+in+Addressing+Metabolic+Disease+Markers", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T15:11:00", "published_display": "26 May 2026 15:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT)", "summary": "Alaunos Therapeutics (NASDAQ: TCRT) announced positive preclinical data for ALN1003, their oral, non-hormonal small-molecule candidate for obesity and metabolic disorders, showing weight loss and improved metabolic markers in mouse studies. Despite promising results, the company ", "url": "https://www.stocktitan.net/sec-filings/TCRT/8-k-alaunos-therapeutics-inc-reports-material-event-46510d7d38cd.html", "source_name": "Stock Titan", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results", "summary": "Alaunos Therapeutics announced positive preclinical data for its obesity drug candidate, ALN1003, showing improvements in weight, body composition, insulin sensitivity, and liver health in mouse studies. The oral treatment aims to address obesity and metabolic disorders without h", "url": "https://stocktwits.com/news-articles/markets/equity/alaunos-therapeutics-tcrt-obesity-drug-study-weight-loss-liver-health-preclinical-aln1003/cZgOaMJReqA", "source_name": "Stocktwits", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports preclinical data for obesity drug candidate ALN1003", "summary": "Alaunos Therapeutics released preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight reduction and improved metabolic markers in diet-induced obesity mouse studies. Despite positive preclinical results, the company faces financial challenge", "url": "https://m.uk.investing.com/news/stock-market-news/alaunos-reports-preclinical-data-for-obesity-drug-candidate-aln1003-93CH-4698708?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alaunos-reports-preclinical-aln1003-data-120000045.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alaunos Therapeutics receives Nasdaq notice for non-compliance with equity rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeVhXNGNiajZwQWcwRHQ5UzdkSTM4cDBIenhiQjVKNTJZQkJ1Vmpsd3llMnYySkVDUzFBYWFkaWNkdHNRQXY4eFVOczB6Tk9Lb1B6UklBQkRzN2Q5b2pPemwyS2Y5cUhZaUNRTE9icTZ5X1VNTkRCLTJsazctWHZnUlMxV2YwWHRFYjRXeXpNcXNIYmUzTTBNLTloOTV1aFRkTy1YbWtBVzEwc2gzT1BoZk1VTEV3NzYzZHl4cjJIX1NUQ3oxd2ZQNVN2ZnNxZjA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Alaunos Therapeutics (TCRT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBhb2RTZGNBMWxkWmlIaUpfWXFrZ3pXbDFJS3hkcE9ZTmxXTGRFRGhnLUQ1RlF2N1VwcmVrVWFadXRrR2ZHR2J3T3BvNThCQ2NzRFJr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:07:16+00:00", "published_display": "25 Apr 2025 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. (TCRT) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE9UdmJuWU9Dc3hSckdIRnp5eHdaR2lzYm5tQ24xRktpRXppMllfNnlQalpoN0YyMUM4a090TjBrWEVJV2xzem1SUFhNVzRFOEV4SmJqeTUyRmllWGxpVXBR?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-05T12:19:13+00:00", "published_display": "05 Apr 2023 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. Financial Statements \u2013 NASDAQ:TCRT", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5WUWtrN1dXZWlNdExvaUt5LXE5OGJhbHF2b01zUHNkclpDcWMyWlQtWXIwakJ3bEpXRlh5cFBzZkt3dFVodjB2MVpjQkFmYjRCWmRqYVJDUlA0a3lSMW5aN3M2MGs0LU9TZU8yd1ZaMmphcjlTR0ZZ?oc=5", "source_name": "TradingView", "published_at": "2022-07-17T18:08:48+00:00", "published_display": "17 Jul 2022 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT: Alaunos Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1FWlZQeTFmWXJTT0hDTTEyZ28tWnhrQ1liby0ycnAxVTlmRk8tS3JvamplN2dqWVpnOGpHWTJhWUtvRmNpQlN1U1ZR?oc=5", "source_name": "Stocktwits", "published_at": "2022-07-11T20:35:49+00:00", "published_display": "11 Jul 2022 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Stock Price Forecast. Should You Buy TCRT?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5EOWN0UnJGY3BBUDU2a1pPbVpPV3BzSU1IVVp2bVRhOWh6MEUzbENIWkdxUEc2cFY2RjZxZi1sTVhTQ3VxWmp6VQ?oc=5", "source_name": "StockInvest.us", "published_at": "2022-03-05T17:43:31+00:00", "published_display": "05 Mar 2022 17:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT Stock Price and Chart \u2014 NASDAQ:TCRT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ScmhuR2ZHMy1Nb0FsWDJHZHMtZFZMVVF5ZVcwWW9DRmR3OVJtZWZpQTMxeGJJOG56bmtSS182OHU3Sm1UQUFnR3MwTlowelVpMEVtaUhXT0hjZnI4?oc=5", "source_name": "TradingView", "published_at": "2022-02-03T03:57:41+00:00", "published_display": "03 Feb 2022 03:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "The article references the price to earnings forward of Alaunos Therapeutics, Inc. under the NASDAQ:TCRT ticker. It appears to be a financial data page from TradingView, indicating that the market for TCRT was closed with no trades. The content primarily consists of navigation an", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-21T17:41:06", "published_display": "21 Jul 2026 17:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "This article provides financial information for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), specifically its Price to Book Forward value. The content is presented within the TradingView platform, noting that market data is provided by ICE Data Services and reference data by FactSe", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-20T19:11:15", "published_display": "20 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "This article provides an enterprise value to revenue forward metric for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It focuses on financial data for the company, accessible through TradingView, and does not contain detailed analysis or news content. The piece appears to be a stub ", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T00:39:26", "published_display": "19 Jul 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com", "summary": "This article announces the filing of a Form 4 for Alaunos Therapeutics Inc. on July 2nd. It is a brief financial news update from Investing.com, providing no further details within the article text itself.", "url": "https://uk.investing.com/news/stock-market-news/form-4-alaunos-therapeutics-inc-for-2-july-93CH-4755887", "source_name": "Investing.com UK", "published_at": "2026-07-06T22:38:00", "published_display": "06 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stock grant to Alaunos (TCRT) CEO issued in lieu of salary", "summary": "Alaunos Therapeutics (TCRT) CEO Holger Weis received a stock grant of 3,880 common shares on June 30, 2026, as compensation in lieu of net salary. The shares were valued at $2.26 each, and following this transaction, Weis directly holds 16,552 common shares. This insider transact", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-ac15cf3b2c20.html", "source_name": "Stock Titan", "published_at": "2026-07-02T21:11:56", "published_display": "02 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT Q4 2023 Earnings: Miss on EPS as Alaunos Continues Pre-Clinical Development - Earnings Per Share", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZzNyR2UxX1pWLTR3cThXYVFnbHk5RjluTGttdEcxLWFGUDRYMVl2RkJpUV9rQmg4eHBGaHlBNEU4UVIyU0VXbWd3dXl4OEllRlljVHA0SkZESWMya2k5RHZYcmdFYk5tb0YxV1d3REtBR2hJM2g2RjdJZThGODJ6WVNkQmpPV0V1SlRuRzlyWHV4U043czgxbzkyakFjaTNaeGt0SkRyMTRLd1FzR0VGRTRMSlZycGREVU5oSjdQbw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-30T07:37:16+00:00", "published_display": "30 Jun 2026 07:37", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study", "summary": "Alaunos Therapeutics announced new preclinical data for its metabolic candidate ALN1003, showing lower liver weight in treated mice after adjusting for body fat percentage in a diet-induced obesity study. This finding supports previous data indicating ALN1003's potential for live", "url": "https://www.sahmcapital.com/news/content/alaunos-reports-new-preclinical-aln1003-data-showing-lower-liver-weight-after-adjustment-for-body-fat-percentage-in-48-day-dio-mouse-study-2026-06-29", "source_name": "Sahm", "published_at": "2026-06-30T06:40:36", "published_display": "30 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) posts new ALN1003 mouse liver and metabolic findings", "summary": "Alaunos Therapeutics announced new preclinical data for its investigational drug ALN1003, showing it significantly reduced liver weight in a diet-induced obesity mouse study, even after adjusting for body fat percentage. This finding is consistent with earlier data indicating low", "url": "https://www.stocktitan.net/sec-filings/TCRT/8-k-alaunos-therapeutics-inc-reports-material-event-70496303fa57.html", "source_name": "Stock Titan", "published_at": "2026-06-29T12:41:43", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) Stock News", "summary": "This page provides news and updates for Alaunos Therapeutics (TCRT) stock, focusing on its transition from TCR-T cell therapy to small-molecule therapeutics for obesity. Recent updates highlight preclinical results for ALN1003, an oral candidate for obesity, showcasing positive m", "url": "https://www.stocktitan.net/news/TCRT/", "source_name": "Stock Titan", "published_at": "2026-06-29T05:40:33", "published_display": "29 Jun 2026 05:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. Actuals & Estimates (NASDAQ:TCRT)", "summary": "This article provides an overview of Alaunos Therapeutics, Inc. (NASDAQ: TCRT) financials and stock performance. It includes details on historical and estimated financial data, stock price movements, volatility, net income, and upcoming earnings dates. The company currently has 1", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:29", "published_display": "26 Jun 2026 08:10", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.32, ranking 126th out of 387 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. The company's latest quarterly revenue saw a 100% year-over-year decr", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/financial-health", "source_name": "TradingKey", "published_at": "2026-06-24T16:10:29", "published_display": "24 Jun 2026 16:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Valuation: PE, PB & Fair Value Analysis", "summary": "Alaunos Therapeutics Inc (TCRT) currently has a valuation score of 6.29, placing it low within the Biotechnology & Medical Research industry. The company's P/E ratio is -1.04, significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-19T04:09:35", "published_display": "19 Jun 2026 04:09", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Alaunos Therapeutics Inc (TCRT), detailing its price momentum score of 5.75 and positioning between resistance at $2.85 and support at $1.68. It includes a summary of technical indicators and moving averages, which overwhelmingly sugg", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T02:09:09", "published_display": "19 Jun 2026 02:09", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Alaunos Therapeutics Inc (TCRT), noting that no earnings forecast score is currently available for the company, contrasting with the Biotechnology & Medical Research industry's average score of 8.15. The report also indicates that re", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T13:40:50", "published_display": "18 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Alaunos Therapeutics Inc (TCRT), identifying its major individual and institutional holders. It provides a breakdown of shareholder types, institutional holdings over several quarters, and recent shareholder activity, including ch", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:09:52", "published_display": "18 Jun 2026 11:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Alaunos Therapeutics Inc (TCRT) stock split history and dividend payouts. The company has not distributed any dividends over the past five years. However, it has had several merger-related stock splits, including a 10-for-1 merger in July 2024", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T03:09:52", "published_display": "18 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "The article discusses the revenue breakdown for Alaunos Therapeutics Inc (TCRT), noting that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly presents the current stock price, market cap, a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T02:09:06", "published_display": "18 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) CEO takes 7,761-share stock grant in lieu of salary", "summary": "Alaunos Therapeutics CEO Holger Weis received a stock grant of 7,761 common shares valued at $2.26 per share on June 12, 2026. This grant was issued in lieu of his net salary, not through an open-market purchase. Following this transaction, Weis directly holds 12,672 shares of Al", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-21c7f242aaf1.html", "source_name": "Stock Titan", "published_at": "2026-06-17T20:39:56", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Alaunos Therapeutics Inc (TCRT)'s institutional confidence score, financial data, and shareholder activity. It lists key institutional shareholders and their recent changes in shareholdings, showing that some increased their st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/sentiment", "source_name": "TradingKey", "published_at": "2026-06-17T02:39:39", "published_display": "17 Jun 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Inc (TCRT) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Alaunos Therapeutics Inc (TCRT), detailing its volatility, financial risk, and investment risk. It highlights the company's beta value of -1.06, indicating it tends to underperform in rising markets but declines less in falling ones. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-tcrt/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-15T12:39:39", "published_display": "15 Jun 2026 12:39", "sentiment": "negative", "sentiment_pct": 38, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Number of shareholders of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT", "summary": "The article concerns the number of shareholders for Alaunos Therapeutics, Inc. (NASDAQ:TCRT). It provides a snapshot of the company's financial overview on TradingView, indicating no trades and a closed market status. The content primarily lists navigation elements and disclaimer", "url": "https://www.tradingview.com/symbols/NASDAQ-TCRT/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-06-14T02:09:08", "published_display": "14 Jun 2026 02:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) falls on cash concerns, Nasdaq delisting risk", "summary": "Alaunos Therapeutics (TCRT) stock fell 6.9% due to concerns over its limited cash reserves and an impending Nasdaq delisting risk, as its market cap is below compliance requirements. The company is attempting to shift investor focus to ALN1003, an early-stage obesity drug, despit", "url": "https://www.bez-kabli.pl/alaunos-therapeutics-tcrt-falls-on-cash-concerns-nasdaq-delisting-risk/", "source_name": "Bez Kabli", "published_at": "2026-06-04T13:09:07", "published_display": "04 Jun 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT - Alaunos Therapeutics Inc Stock Price and Quote", "summary": "This article provides comprehensive financial data, stock performance metrics, and a news feed for Alaunos Therapeutics Inc (TCRT). It includes details on the company's oncology-focused cell therapy developments, recent preclinical study results for ALN1003, and past analyst rati", "url": "https://finviz.com/stock?t=TCRT", "source_name": "Finviz", "published_at": "2026-05-30T18:11:34", "published_display": "30 May 2026 18:11", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) Dips 6.86% as Stock Approaches Critical Support Level - Short Setup Alerts", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNV29ibEJHVTlXdjc0a282NEljVExZRWNOZ1Q4eC1TMXBXcnlBY21PQ2xTRmI2dF9xZ2NRSjJtSU5WZ3lDNXZ3cjJDaXFMMG41dW1aZFRHX18zMmE5Wi1RVTBaSGZ0bzRfSDlSX1VxQjNtVno3X1lDbWFuaEVNSVJMWTNKTXc3bGx1Rl9uM2lFRE42dDQ0SmdVejcxMURjRTR0RlEzM2RqaDRTSXRqeTFwUE8zM1pjbkx6NVdtUnh3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) CEO takes 3,700 shares instead of salary", "summary": "Alaunos Therapeutics (TCRT) CEO Holger Weis received 3,700 shares of common stock at $2.37 per share on May 22, 2026, as compensation in lieu of his net salary. Following this transaction, Weis directly holds 4,911 shares of Alaunos common stock. This insider activity was reporte", "url": "https://www.stocktitan.net/sec-filings/TCRT/form-4-alaunos-therapeutics-inc-insider-trading-activity-202df3217916.html", "source_name": "Stock Titan", "published_at": "2026-05-27T20:39:23", "published_display": "27 May 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers", "summary": "Alaunos Biomedical announced positive preclinical results for its new obesity drug, which demonstrated significant reductions in body weight, improved liver health, and enhanced insulin sensitivity in animal models. These findings suggest the drug could be a promising candidate f", "url": "https://www.msn.com/en-us/health/other/alaunos-reports-positive-preclinical-obesity-drug-results-across-weight-liver-insulin-markers/ar-AA247lNo?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "source_name": "MSN", "published_at": "2026-05-27T17:39:23", "published_display": "27 May 2026 17:39", "sentiment": "positive", "sentiment_pct": 86, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports preclinical data for obesity drug candidate ALN1003 By Investing.com", "summary": "Alaunos Therapeutics has released integrated preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight and liver weight reductions in diet-induced obesity mouse studies. Despite these promising results and potential benefits for metabolic issu", "url": "https://za.investing.com/news/stock-market-news/alaunos-reports-preclinical-data-for-obesity-drug-candidate-aln1003-93CH-4300135", "source_name": "Investing.com South Africa", "published_at": "2026-05-26T17:10:24", "published_display": "26 May 2026 17:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alaunos-reports-broad-metabolic-improvements-150100200.html", "source_name": "GlobeNewswire", "published_at": "2026-05-26T15:01:00+00:00", "published_display": "26 May 2026 15:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Reports Positive Preclinical Results for ALN1003 in Addressing Metabolic Disease Markers", "summary": "Alaunos Therapeutics announced positive preclinical results for ALN1003, an oral treatment for obesity and metabolic disorders, showing significant reductions in body weight and fat mass, improved insulin sensitivity, and enhanced liver health in diet-induced obese mice. While th", "url": "https://www.quiverquant.com/news/Alaunos+Therapeutics+Reports+Positive+Preclinical+Results+for+ALN1003+in+Addressing+Metabolic+Disease+Markers", "source_name": "Quiver Quantitative", "published_at": "2026-05-26T15:11:00", "published_display": "26 May 2026 15:11", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALN1003 obesity data and cash runway update from Alaunos (NASDAQ: TCRT)", "summary": "Alaunos Therapeutics (NASDAQ: TCRT) announced positive preclinical data for ALN1003, their oral, non-hormonal small-molecule candidate for obesity and metabolic disorders, showing weight loss and improved metabolic markers in mouse studies. Despite promising results, the company ", "url": "https://www.stocktitan.net/sec-filings/TCRT/8-k-alaunos-therapeutics-inc-reports-material-event-46510d7d38cd.html", "source_name": "Stock Titan", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results", "summary": "Alaunos Therapeutics announced positive preclinical data for its obesity drug candidate, ALN1003, showing improvements in weight, body composition, insulin sensitivity, and liver health in mouse studies. The oral treatment aims to address obesity and metabolic disorders without h", "url": "https://stocktwits.com/news-articles/markets/equity/alaunos-therapeutics-tcrt-obesity-drug-study-weight-loss-liver-health-preclinical-aln1003/cZgOaMJReqA", "source_name": "Stocktwits", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos reports preclinical data for obesity drug candidate ALN1003", "summary": "Alaunos Therapeutics released preclinical data for its oral obesity drug candidate, ALN1003, showing significant body weight reduction and improved metabolic markers in diet-induced obesity mouse studies. Despite positive preclinical results, the company faces financial challenge", "url": "https://m.uk.investing.com/news/stock-market-news/alaunos-reports-preclinical-data-for-obesity-drug-candidate-aln1003-93CH-4698708?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-05-26T15:09:20", "published_display": "26 May 2026 15:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/alaunos-reports-preclinical-aln1003-data-120000045.html", "source_name": "GlobeNewswire", "published_at": "2026-05-18T12:00:00+00:00", "published_display": "18 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics receives Nasdaq notice for non-compliance with equity rule", "summary": "", "url": "https://news.google.com/rss/articles/CBMizwFBVV95cUxNeVhXNGNiajZwQWcwRHQ5UzdkSTM4cDBIenhiQjVKNTJZQkJ1Vmpsd3llMnYySkVDUzFBYWFkaWNkdHNRQXY4eFVOczB6Tk9Lb1B6UklBQkRzN2Q5b2pPemwyS2Y5cUhZaUNRTE9icTZ5X1VNTkRCLTJsazctWHZnUlMxV2YwWHRFYjRXeXpNcXNIYmUzTTBNLTloOTV1aFRkTy1YbWtBVzEwc2gzT1BoZk1VTEV3NzYzZHl4cjJIX1NUQ3oxd2ZQNVN2ZnNxZjA?oc=5", "source_name": "Investing.com", "published_at": "2026-04-15T07:00:00+00:00", "published_display": "15 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics (TCRT) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBhb2RTZGNBMWxkWmlIaUpfWXFrZ3pXbDFJS3hkcE9ZTmxXTGRFRGhnLUQ1RlF2N1VwcmVrVWFadXRrR2ZHR2J3T3BvNThCQ2NzRFJr?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-25T00:07:16+00:00", "published_display": "25 Apr 2025 00:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. (TCRT) Stock Forecast & Price Prediction 2026\u20132030", "summary": "", "url": "https://news.google.com/rss/articles/CBMiX0FVX3lxTE9UdmJuWU9Dc3hSckdIRnp5eHdaR2lzYm5tQ24xRktpRXppMllfNnlQalpoN0YyMUM4a090TjBrWEVJV2xzem1SUFhNVzRFOEV4SmJqeTUyRmllWGxpVXBR?oc=5", "source_name": "CoinCodex", "published_at": "2023-04-05T12:19:13+00:00", "published_display": "05 Apr 2023 12:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics, Inc. Financial Statements \u2013 NASDAQ:TCRT", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE5WUWtrN1dXZWlNdExvaUt5LXE5OGJhbHF2b01zUHNkclpDcWMyWlQtWXIwakJ3bEpXRlh5cFBzZkt3dFVodjB2MVpjQkFmYjRCWmRqYVJDUlA0a3lSMW5aN3M2MGs0LU9TZU8yd1ZaMmphcjlTR0ZZ?oc=5", "source_name": "TradingView", "published_at": "2022-07-17T18:08:48+00:00", "published_display": "17 Jul 2022 18:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT: Alaunos Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1FWlZQeTFmWXJTT0hDTTEyZ28tWnhrQ1liby0ycnAxVTlmRk8tS3JvamplN2dqWVpnOGpHWTJhWUtvRmNpQlN1U1ZR?oc=5", "source_name": "Stocktwits", "published_at": "2022-07-11T20:35:49+00:00", "published_display": "11 Jul 2022 20:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Alaunos Therapeutics Stock Price Forecast. Should You Buy TCRT?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSEFVX3lxTE5EOWN0UnJGY3BBUDU2a1pPbVpPV3BzSU1IVVp2bVRhOWh6MEUzbENIWkdxUEc2cFY2RjZxZi1sTVhTQ3VxWmp6VQ?oc=5", "source_name": "StockInvest.us", "published_at": "2022-03-05T17:43:31+00:00", "published_display": "05 Mar 2022 17:43", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "TCRT Stock Price and Chart \u2014 NASDAQ:TCRT", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5ScmhuR2ZHMy1Nb0FsWDJHZHMtZFZMVVF5ZVcwWW9DRmR3OVJtZWZpQTMxeGJJOG56bmtSS182OHU3Sm1UQUFnR3MwTlowelVpMEVtaUhXT0hjZnI4?oc=5", "source_name": "TradingView", "published_at": "2022-02-03T03:57:41+00:00", "published_display": "03 Feb 2022 03:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 89, "total_relevant": 49, "sentiment_summary": {"positive": 8, "negative": 10, "neutral": 31, "score": 50, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 76, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.96, "count": 24}, {"event": "general", "label": "Market update", "weight": 10.45, "count": 19}, {"event": "guidance", "label": "Guidance", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 8, "negative_events": 10}, "market_context": {"has_market_context": true, "latest_close": 2.05, "latest_week": "2026-07-17", "one_week_move": 0.0, "four_week_move": -4.7, "twelve_week_move": -25.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -1.289038, "market_dynamics_buy_signal": false, "relative_strength": -33.691199, "fair_value_gap": -73.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 35.5363, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.0% over one week, -4.7% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 47, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 7}, {"label": "Market source", "count": 6}, {"label": "Investing.com UK", "count": 2}, {"label": "dars.gov.et", "count": 2}, {"label": "GlobeNewswire", "count": 2}, {"label": "Stocktwits", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 40}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 19}, {"label": "Guidance", "count": 2}, {"label": "Regulatory and legal", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "40", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+0.0% over one week, -4.7% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of Alaunos Therapeutics, Inc. \u2013 NASDAQ:TCRT"}], "updated_at": "2026-07-23T06:16:50.468288+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}